91300 (Pfizer Vaccine) |
Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use (Report with administration
codes: 0001A-First administration and 0002A-Second administration). Eff. 12/11/2020 |
0001A (Admin1) |
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted;
first dose. (Report with administration of Pfizer vaccine 91300) |
0002A (Admin2) |
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted;
second dose. (Report with administration of Pfizer vaccine 91300) |
91307 (Pfizer vaccine youth dose, ages 5-11 years) |
Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, preservative free, one-third adult dose, diluent reconstituted, for intramuscular use (Report with administration
codes: 0071A-First administration and 0072A-Second administration). Eff. 10/29/2021 |
0071A (Admin1)
|
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, one-third adult dose, diluent
reconstituted; first dose. (Report with administration of Pfizer vaccine pediatric dose 91307) |
0072A (Admin2)
|
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, one-third adult dose, diluent
reconstituted; second dose. (Report with administration of Pfizer vaccine pediatric dose 91307) |
91308 (Pfizer vaccine pediatric dose, 6 months to 4 years) |
Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, preservative free, diluent reconstituted, for intramuscular use (Report with administration codes: 0081A-First
administration and 0082A-Second administration and 0083A-Third administration). |
0081A (Admin1)
|
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free; first dose. (Report
with administration of Pfizer vaccine child dose 91308) |
0082A (Admin2)
|
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free; second dose.
(Report with administration of Pfizer vaccine child dose 91308) |
0083A (Admin2)
|
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free; third dose.
(Report with administration of Pfizer vaccine child dose 91308)
|
|
91301 (Moderna vaccine) |
Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use (Report with administration codes: 0011A-First
administration and 0012A-Second administration) Eff. 12/18/2020 |
0011A (Admin1) |
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose.
(Report with administration of Moderna vaccine 91301) |
0012A (Admin2)
|
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose. (Report with administration of Moderna vaccine 91301) |
91307 (Moderna vaccine youth 5-11) |
Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, preservative free, for intramuscular use for youth 5-11. (Report with administration codes: 0071A-First administration
and 0072A-Second administration)
Effective October 20, 2021 |
0071A (Admin1)
|
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free;
first dose. (Report with administration of Moderna vaccine 91307) |
0072A (Admin2)
|
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free; second dose.
(Report with administration of Moderna vaccine 91307)
|
|
91311 (Moderna vaccine for children 6 months to 5 years) |
Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, preservative free, for intramuscular use for children 6 months-5 years. (Report with administration codes: 0111A-First
administration and 0112A-Second administration)
|
0111A (Admin1)
|
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free;
first dose. (Report with administration of Moderna vaccine 91311) |
0112A (Admin2)
|
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free;
second dose. (Report with administration of Moderna vaccine 91311) |
91303
(Janssen /Johnson & Johnson vaccine) |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, for intramuscular use.
Eff. Date: 2/27/2021 |
0031A |
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010
viral particles/0.5mL dosage, single dose. Eff. Date: 2/27/2021 |
0003A - PFIZER
THIRD DOSE |
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS[1]CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA[1]LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent
reconstituted (Effective
August 12, 2021) |
00073A - PFIZER PEDIATRIC
THIRD DOSE CODE AGES 5-11 |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris[1]sucrose formulation, for intramuscular
use (Effective January 3, 2022)
|
00074A - PFIZER PEDIATRIC
FOURTH DOSE CODE AGES 5-11 |
Severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein,
preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris[1]sucrose
formulation, for intramuscular use (Effective May 17, 2022)
|
0013A - MODERNA
THIRD DOSE |
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV[1]2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; (Effective August 12, 2021) |
0004A - BOOSTER DOSE CODE |
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS[1]CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA[1]LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent
reconstituted. (Effective Sept. 25, 2021) |
0094A - 2nd BOOSTER DOSE CODE |
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS[1]CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA[1]LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent
reconstituted.
(Effective
March 29, 2022) |